SCHEMBL4008015

SCHEMBL4008015

CCCC[C@@H](C)C[C@H](CNC(=O)[C@@H](N)C(C)C)CC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 3/20 0.44
DPP8 Q6V1X1 2/20 0.44
DPP4 P27487 1/20 0.44
DPP9 Q86TI2 1/20 0.44
SLC15A1 P46059 1/20 0.36
GPR88 Q9GZN0 1/20 0.36
PDF Q9HBH1 1/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
CACNA2D1 P54289 2/20 0.33
CACNB3 P54284 1/20 0.33
CACNA1C Q13936 1/20 0.33
PGR P06401 1/20 0.33
ADRA1A P35348 1/20 0.33
HTR2B P41595 1/20 0.33
CACNA2D2 Q9NY47 1/20 0.33
GPR84 Q9NQS5 4/20 0.33
MMP2 P08253 4/20 0.32
MMP3 P08254 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008978 1.00 DPP7 (0.44) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4009524 1.00 DPP7 (0.44) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4014989 0.92 GPR88 (0.41) DPP7DPP8DPP4DPP9GPR88
SCHEMBL4011839 0.92 GPR88 (0.41) DPP7DPP8DPP4DPP9GPR88
SCHEMBL4008700 0.92 GPR88 (0.41) DPP7DPP8DPP4DPP9GPR88
SCHEMBL4010429 0.90 GPR88 (0.38) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4007908 0.90 GPR88 (0.38) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4014944 0.90 GPR88 (0.38) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4014281 0.89 SLC15A1 (0.44) DPP7DPP8DPP4DPP9SLC15A1
SCHEMBL4007904 0.89 SLC15A1 (0.44) DPP7DPP8DPP4DPP9SLC15A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US claimed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US claimed
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US disclosed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP disclosed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A DPP7 1105/4885DPP8 2187/4885DPP4 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.